ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
USA - NASDAQ:ACAD - US0042251084 - Common Stock
24.42 USD
-0.33 (-1.35%)
24.42 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to ACAD. ACAD was compared to 540 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make ACAD a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year ACAD was profitable.
ACAD had a positive operating cash flow in the past year.
ACAD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ACAD reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 18.13%, ACAD belongs to the best of the industry, outperforming 96.48% of the companies in the same industry.
ACAD has a Return On Equity of 27.01%. This is amongst the best in the industry. ACAD outperforms 97.04% of its industry peers.
ACAD has a better Return On Invested Capital (8.85%) than 93.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROIC | 8.85% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACAD has a Profit Margin of 21.80%. This is amongst the best in the industry. ACAD outperforms 95.00% of its industry peers.
The Operating Margin of ACAD (8.86%) is better than 91.67% of its industry peers.
ACAD has a better Gross Margin (91.97%) than 92.41% of its industry peers.
In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
2. Health
2.1 Basic Checks
ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ACAD has more shares outstanding than it did 1 year ago.
ACAD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 5.44 indicates that ACAD is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 5.44, ACAD is doing good in the industry, outperforming 76.48% of the companies in the same industry.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.44 |
ROIC/WACC0.92
WACC9.62%
2.3 Liquidity
ACAD has a Current Ratio of 2.91. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD's Current ratio of 2.91 is on the low side compared to the rest of the industry. ACAD is outperformed by 64.63% of its industry peers.
A Quick Ratio of 2.83 indicates that ACAD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.83, ACAD is doing worse than 64.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 150.00% over the past year.
The Revenue has grown by 14.41% in the past year. This is quite good.
Measured over the past years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 23.08% on average per year.
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)14.41%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%9.34%
3.2 Future
ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.29% yearly.
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.25% yearly.
EPS Next Y19.98%
EPS Next 2Y34.15%
EPS Next 3Y43.65%
EPS Next 5Y41.29%
Revenue Next Year9.96%
Revenue Next 2Y10.97%
Revenue Next 3Y11.46%
Revenue Next 5Y11.25%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 54.27 indicates a quite expensive valuation of ACAD.
ACAD's Price/Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 91.30% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.38, ACAD is valued quite expensively.
A Price/Forward Earnings ratio of 28.27 indicates a quite expensive valuation of ACAD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 91.30% of the companies listed in the same industry.
ACAD's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.27 | ||
| Fwd PE | 28.27 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 92.59% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ACAD is valued cheaper than 92.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 46.64 | ||
| EV/EBITDA | 27.95 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ACAD does not grow enough to justify the current Price/Earnings ratio.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
ACAD's earnings are expected to grow with 43.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.72
PEG (5Y)N/A
EPS Next 2Y34.15%
EPS Next 3Y43.65%
5. Dividend
5.1 Amount
No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.42
-0.33 (-1.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners103.86%
Inst Owner Change-2.36%
Ins Owners0.31%
Ins Owner Change2.18%
Market Cap4.12B
Analysts76.15
Price Target30.71 (25.76%)
Short Float %5.53%
Short Ratio4.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.63%
Min EPS beat(2)-3.19%
Max EPS beat(2)14.46%
EPS beat(4)2
Avg EPS beat(4)-13.96%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)7.72%
EPS beat(12)7
Avg EPS beat(12)13.12%
EPS beat(16)10
Avg EPS beat(16)17.21%
Revenue beat(2)1
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.93%
Max Revenue beat(2)0.08%
Revenue beat(4)1
Avg Revenue beat(4)-2.63%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)4
Avg Revenue beat(8)-0.28%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)7
Avg Revenue beat(16)-1.31%
PT rev (1m)5.24%
PT rev (3m)12.68%
EPS NQ rev (1m)6.66%
EPS NQ rev (3m)7.84%
EPS NY rev (1m)7.65%
EPS NY rev (3m)-3.06%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0.65%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.27 | ||
| Fwd PE | 28.27 | ||
| P/S | 4.04 | ||
| P/FCF | 46.64 | ||
| P/OCF | 21.91 | ||
| P/B | 5.01 | ||
| P/tB | 5.82 | ||
| EV/EBITDA | 27.95 |
EPS(TTM)0.45
EY1.84%
EPS(NY)0.86
Fwd EY3.54%
FCF(TTM)0.52
FCFY2.14%
OCF(TTM)1.11
OCFY4.56%
SpS6.04
BVpS4.87
TBVpS4.2
PEG (NY)2.72
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROCE | 10.08% | ||
| ROIC | 8.85% | ||
| ROICexc | 59.33% | ||
| ROICexgc | 412.73% | ||
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% | ||
| FCFM | 8.67% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score6
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 729.13% | ||
| Cap/Sales | 9.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 180.83% | ||
| Profit Quality | 39.76% | ||
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 | ||
| Altman-Z | 5.44 |
F-Score6
WACC9.62%
ROIC/WACC0.92
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)1.86%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y19.98%
EPS Next 2Y34.15%
EPS Next 3Y43.65%
EPS Next 5Y41.29%
Revenue 1Y (TTM)14.41%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%9.34%
Revenue Next Year9.96%
Revenue Next 2Y10.97%
Revenue Next 3Y11.46%
Revenue Next 5Y11.25%
EBIT growth 1Y307.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.34%
EBIT Next 3Y29.08%
EBIT Next 5Y49.91%
FCF growth 1Y218.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y647.78%
OCF growth 3YN/A
OCF growth 5YN/A